Pzena Investment Management LLC Makes New Investment in Teleflex Incorporated $TFX

Key Points

• Pzena Investment Management LLC acquired 356,107 shares of Teleflex Incorporated, valued at approximately $42.15 million, representing about 0.81% of the company's stock.
• Teleflex recently declared a quarterly dividend of $0.34 per share, yielding approximately 1.1% annually, with a dividend payout ratio of 32%.
• The company's stock has declined 4.1%, opening at $119.54, and has shown fluctuations with a 52-week range between $108.90 and $241.41.

Pzena Investment Management LLC acquired a new position in shares of Teleflex Incorporated (NYSE:TFX - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 356,107 shares of the medical technology company's stock, valued at approximately $42,149,000. Pzena Investment Management LLC owned approximately 0.81% of Teleflex at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. UMB Bank n.a. lifted its stake in shares of Teleflex by 3,763.6% in the first quarter. UMB Bank n.a. now owns 425 shares of the medical technology company's stock worth $59,000 after acquiring an additional 414 shares in the last quarter. Yousif Capital Management LLC lifted its stake in shares of Teleflex by 149.8% in the first quarter. Yousif Capital Management LLC now owns 18,031 shares of the medical technology company's stock worth $2,492,000 after acquiring an additional 10,813 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Teleflex in the first quarter worth about $1,366,000. CX Institutional acquired a new position in shares of Teleflex in the first quarter worth about $105,000. Finally, Fifth Third Bancorp lifted its stake in shares of Teleflex by 7.6% in the first quarter. Fifth Third Bancorp now owns 4,142 shares of the medical technology company's stock worth $572,000 after acquiring an additional 293 shares in the last quarter. Institutional investors and hedge funds own 95.62% of the company's stock.

Teleflex Stock Down 4.1%

NYSE:TFX opened at $119.54 on Monday. The firm has a market capitalization of $5.28 billion, a PE ratio of 28.13, a price-to-earnings-growth ratio of 1.67 and a beta of 1.05. The stock has a 50 day moving average of $124.30 and a 200-day moving average of $124.07. Teleflex Incorporated has a 52 week low of $108.90 and a 52 week high of $241.41. The company has a current ratio of 2.41, a quick ratio of 1.44 and a debt-to-equity ratio of 0.42.

Teleflex (NYSE:TFX - Get Free Report) last posted its earnings results on Thursday, July 31st. The medical technology company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.36 by $0.37. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The firm had revenue of $780.90 million for the quarter, compared to analysts' expectations of $771.53 million. During the same period last year, the firm earned $3.42 EPS. The firm's revenue was up 4.2% compared to the same quarter last year. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. Analysts predict that Teleflex Incorporated will post 13.98 EPS for the current year.

Teleflex Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, September 15th. Shareholders of record on Friday, August 15th were paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend was Friday, August 15th. Teleflex's dividend payout ratio (DPR) is presently 32.00%.

Insider Activity

In related news, Director Andrew A. Krakauer acquired 1,000 shares of Teleflex stock in a transaction dated Tuesday, August 5th. The stock was acquired at an average cost of $115.25 per share, with a total value of $115,250.00. Following the purchase, the director directly owned 7,192 shares in the company, valued at $828,878. The trade was a 16.15% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Liam Kelly acquired 1,500 shares of Teleflex stock in a transaction dated Tuesday, August 5th. The shares were bought at an average cost of $115.07 per share, with a total value of $172,605.00. Following the completion of the purchase, the chief executive officer owned 45,267 shares in the company, valued at approximately $5,208,873.69. This represents a 3.43% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 5,500 shares of company stock worth $633,590 in the last quarter. 1.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on TFX. Wells Fargo & Company cut their price target on Teleflex from $137.00 to $131.00 and set an "equal weight" rating on the stock in a research note on Friday, August 1st. Mizuho boosted their price target on Teleflex from $130.00 to $135.00 and gave the stock a "neutral" rating in a research note on Friday, August 1st. Royal Bank Of Canada boosted their price target on Teleflex from $130.00 to $135.00 and gave the stock a "sector perform" rating in a research note on Friday, August 1st. Wall Street Zen cut Teleflex from a "strong-buy" rating to a "buy" rating in a research note on Monday, September 15th. Finally, Zacks Research cut Teleflex from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 30th. One analyst has rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, Teleflex presently has a consensus rating of "Reduce" and an average target price of $141.57.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.